News | February 08, 2025
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Indoco is comprehensively working on the remedial action plan
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Subscribe To Our Newsletter & Stay Updated
